United Kingdom · Question · Written question
UIN 87906
Abiraterone: Finance
Original
Introduced
4 November 2025
Last action
17 November 2025 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
17 November 2025
Summary
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 October 2025 to Question 83371 on Abiraterone: Finance, what steps he is taking to secure recurrent budget allocation for abiraterone for use in cases of high-risk non-
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
4 November 2025
Written question
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 30 October 2025 to Question 83371 on Abiraterone: Finance, what steps he is taking to secure recurrent budget allocation for abiraterone for use in cases of high-risk non-
Source: Commons
17 November 2025
Answer
Abiraterone is not licensed for use in the treatment of high-risk, non-metastatic hormone-sensitive prostate cancer, and as such, cannot be evaluated by the National Institute for Health and Care Excellence (NICE) for routine use on the National Health Se...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2025-11-04/87906
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1848180
- uk · wq-1848180 · source updated 17 November 2025